PDI seeks new CEO following Marquad retirement

Share this article:
Contract sales firm PDI has announced the retirement of its CEO Michael Marquard.

In a statement issued by the company today, PDI said it will immediately begin a search for a new CEO. While the search is under way, John Dugan, chairman of the board, former CEO and founder of the company, will play a more active role in overseeing operations, PDI said. Jeffrey Smith, PDI's EVP, finance and CFO, has been named interim CEO.

Marquad joined PDI as CEO in May 2006. Prior to joining PDI he was president of Mylan Bertek Pharmaceuticals, VP of Mylan Laboratories and SVP of US sales for Wyeth, where he led a 5,000-person US sales organization. Marquard began his career as a medical sales rep with Lederle Laboratories.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...